Incyte’s Oral JAK1 Inhibitor Shows Potential In Facial, Full Body Vitiligo

11 Oct 2023

After promising Phase IIb 24-week data with povorcitinib, Incyte unveiled 52-week data indicating greater improvement with longer-term therapy and plans to initiate a Phase III trial.

Vitiligo — Incyte is hoping to bring vitiligo patients multiple therapeutic options • Source: Shutterstock

Incyte’s Oral JAK1 Inhibitor Shows Potential In Facial, Full Body Vitiligo

More from Clinical Trials

More from R&D